Predictions
Lexicon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.15
11.03.23
11.03.23
-
11.03.24
11.03.24
18.11%
12.03.24
12.03.24
Orthofix Medical Inc.
Start price
Target price
Perf. (%)
€16.20
11.03.23
11.03.23
-
11.03.24
11.03.24
-20.37%
12.03.24
12.03.24
United Insurance Holdings Corp
Start price
Target price
Perf. (%)
€2.24
11.03.23
11.03.23
-
11.03.24
11.03.24
308.48%
12.03.24
12.03.24
Galmed Pharmaceuticals Ltd.
Start price
Target price
Perf. (%)
€0.42
11.03.23
11.03.23
-
11.03.24
11.03.24
-21.70%
12.03.24
12.03.24
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€435.50
11.03.23
11.03.23
-
11.03.24
11.03.24
2.76%
12.03.24
12.03.24
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€435.50
11.03.23
11.03.23
-
11.03.24
11.03.24
2.76%
12.03.24
12.03.24
Amicus Therapeutics Inc.
Start price
Target price
Perf. (%)
€10.70
11.03.23
11.03.23
-
11.03.24
11.03.24
2.80%
12.03.24
12.03.24
InVivo Therapeutics Holdings
Start price
Target price
Perf. (%)
€0.94
11.03.23
11.03.23
-
11.03.24
11.03.24
-76.68%
12.03.24
12.03.24
Sapiens International Corporation NV
Start price
Target price
Perf. (%)
€18.30
11.03.23
11.03.23
-
11.03.24
11.03.24
51.91%
12.03.24
12.03.24
Canadian Solar Inc.
Start price
Target price
Perf. (%)
€36.73
11.03.23
11.03.23
€30.00
11.03.24
11.03.24
0.48%
18.04.23
18.04.23
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Kandi Technologies Corp.
Start price
Target price
Perf. (%)
€2.11
11.03.23
11.03.23
€2.00
11.03.24
11.03.24
21.05%
18.04.23
18.04.23
EBIT growth >5% per year expected
Innovative
Future proof or reliable business model
Sustainability is little important
Canopy Growth Corp
Start price
Target price
Perf. (%)
€1.93
11.03.23
11.03.23
€0.30
11.03.24
11.03.24
-77.19%
08.07.23
08.07.23
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Bed Bath & Beyond Inc.
Start price
Target price
Perf. (%)
€1.35
11.03.23
11.03.23
€1.90
11.03.24
11.03.24
-78.15%
18.04.23
18.04.23
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Very low/no dividend yield expected
very negative Cash Flow expected